Teva Pharmaceutical Industries Limited (TEVA) Stock Forecast
Data as of Aug 5, 2026Healthcare · Current price $34.42 (-0.12%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
TEVA vs Sector & Market
| Metric | TEVA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 9 | 8 | 18 |
| Target Upside | +19.9% | +16316.1% | +17.1% |
| P/E Ratio | 25.59 | 3.30 | 36.31 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $4.23B | $4.27B | $4.32B | 4 |
| 2026-12-31 | $4.26B | $4.31B | $4.35B | 5 |
| 2027-03-31 | $3.89B | $3.94B | $3.98B | 3 |
| 2027-06-30 | $4.19B | $4.23B | $4.28B | 3 |
| 2027-09-30 | $4.44B | $4.49B | $4.54B | 3 |
| 2027-12-31 | $4.43B | $4.48B | $4.53B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.75 | $0.76 | $0.77 | 3 |
| 2026-12-31 | $0.79 | $0.80 | $0.81 | 4 |
| 2027-03-31 | $0.58 | $0.58 | $0.59 | 2 |
| 2027-06-30 | $0.72 | $0.73 | $0.74 | 2 |
| 2027-09-30 | $0.86 | $0.87 | $0.89 | 2 |
| 2027-12-31 | $0.90 | $0.92 | $0.93 | 2 |
Frequently Asked Questions
What is the analyst consensus for TEVA?
The consensus among 9 analysts covering Teva Pharmaceutical Industries Limited (TEVA) is Buy with an average price target of $40.00.
What is the highest price target for TEVA?
The highest analyst price target for TEVA is $42.00.
What is the lowest price target for TEVA?
The lowest analyst price target for TEVA is $36.00.
How many analysts cover TEVA?
9 analysts have issued ratings for Teva Pharmaceutical Industries Limited in the past 12 months.
Is TEVA a buy or sell right now?
Based on 9 analyst ratings, TEVA has a consensus rating of Buy (2.00/5) with a +19.9% upside to the consensus target of $40.00.
What are the earnings estimates for TEVA?
Analysts estimate TEVA will report EPS of $0.76 for the period ending 2026-09-30, with revenue estimated at $4.27B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.